Skip to main content
. Author manuscript; available in PMC: 2017 Sep 5.
Published in final edited form as: Leuk Res. 2014 Sep 10;38(11):1332–1341. doi: 10.1016/j.leukres.2014.09.001

Figure 2. SGI-110 treatment induces hypomethylation and expression of NY-ESO-1 and MAGE-A3/A6 in U937 xenografts treated using a daily x 5 schedule.

Figure 2

SGI-110 at varying doses (3, 6.1,10 mg/kg) or DAC (2.5 mg/kg) was administered for five days (days 1–5); on day 7 after treatment, tumors were harvested. A) LINE-1 and NY-ESO-1 promoter methylation bisulfite pyrosequencing; MAGE-A3/6 by MSP (Representative of two experiments) B) NY-ESO-1 and MAGE-A3/6 mRNA quantified by qRT-PCR. C) NY-ESO-1 and MAGE-A protein expression by western blotting. Data is representative of 3 animals/group. *p<0.05 vs. vehicle.